Sierra Legacy Group Buys 2,041 Shares of West Pharmaceutical Services, Inc. $WST

Sierra Legacy Group raised its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 58.6% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 5,526 shares of the medical instruments supplier’s stock after acquiring an additional 2,041 shares during the period. Sierra Legacy Group’s holdings in West Pharmaceutical Services were worth $1,209,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in the business. Zions Bancorporation National Association UT bought a new position in West Pharmaceutical Services in the 1st quarter worth approximately $25,000. Quarry LP bought a new stake in shares of West Pharmaceutical Services during the first quarter valued at about $27,000. CVA Family Office LLC grew its stake in West Pharmaceutical Services by 573.3% during the second quarter. CVA Family Office LLC now owns 202 shares of the medical instruments supplier’s stock valued at $44,000 after acquiring an additional 172 shares in the last quarter. Cromwell Holdings LLC raised its position in shares of West Pharmaceutical Services by 587.5% in the second quarter. Cromwell Holdings LLC now owns 220 shares of the medical instruments supplier’s stock worth $48,000 after buying an additional 188 shares in the last quarter. Finally, Brooklyn Investment Group grew its position in West Pharmaceutical Services by 83.3% in the first quarter. Brooklyn Investment Group now owns 275 shares of the medical instruments supplier’s stock worth $61,000 after acquiring an additional 125 shares in the last quarter. 93.90% of the stock is owned by hedge funds and other institutional investors.

West Pharmaceutical Services Stock Down 0.9%

NYSE:WST opened at $260.08 on Wednesday. The firm has a market capitalization of $18.71 billion, a P/E ratio of 38.53, a PEG ratio of 4.09 and a beta of 1.08. The company’s fifty day moving average price is $269.06 and its 200-day moving average price is $242.69. West Pharmaceutical Services, Inc. has a 1-year low of $187.43 and a 1-year high of $348.90. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.87 and a quick ratio of 2.18.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, October 23rd. The medical instruments supplier reported $1.96 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.29. The company had revenue of $804.60 million for the quarter, compared to the consensus estimate of $788.42 million. West Pharmaceutical Services had a return on equity of 18.16% and a net margin of 16.29%.The firm’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same period last year, the firm earned $1.85 EPS. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. As a group, equities research analysts anticipate that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have commented on WST. Rothschild & Co Redburn assumed coverage on West Pharmaceutical Services in a report on Monday, September 15th. They issued a “buy” rating and a $311.00 target price on the stock. Deutsche Bank Aktiengesellschaft set a $345.00 target price on shares of West Pharmaceutical Services and gave the stock a “buy” rating in a report on Friday, October 24th. TD Cowen initiated coverage on shares of West Pharmaceutical Services in a research report on Wednesday, October 29th. They issued a “buy” rating and a $350.00 price objective on the stock. Evercore ISI lifted their price target on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an “outperform” rating in a report on Thursday, October 23rd. Finally, KeyCorp upped their target price on West Pharmaceutical Services from $325.00 to $350.00 and gave the company an “overweight” rating in a research report on Friday, October 24th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $349.20.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.